Join now at #THT2022 as @HFpEF describes the results of the REDUCE HF-LAP II trial: the largest contemporary HFpEF device based trial.

Not the exclusion criteria for patients that may not tolerate a right sided volume load were defined by resting RA pressure, TR severity and PVR This was a sick population with a median resting PCWP > 18. Meticulous definition of HFpEF with Exercise hemodynamics

The LA strain was quite low in both arms and could that affect who would respond @RBPatelMD?

Join now as Dr. Mann gives a keynote on HF in 2022 in the era of SGLT2i #THT2022

“Predicting the future isn’t what it used to be” - Yogi Berra

In era where definitions of HF are becoming blurred, how do we define the role of therapies? A talk pertinent for all cardiologists Followed by @NirUrielMD talking about the future of HF and pointing out this fantastic paper from @HRRosenblum on a device-based approach to ADHF w/ the DRI2️⃣P2️⃣S approach

Read paper here: ahajournals.org/doi/full/10.11…

@BrenerMickey @ersied727 @zilgiovineMD @tremartyn @AHajduczok